JNP-0201 is an estrogen + progesterone IVR for hormone replacement therapy.

Valued at $2.2 billioni, the U.S. hormone replacement therapy (HRT) market is largely serviced by compounding pharmacies, with no FDA-approved combination products delivering natural hormones available.

JNP-0201 is a two-segment IVR comprised of an estradiol segment to address the symptoms of menopause coupled with a natural progesterone segment to protect against endometrial hyperplasia. We expect JNP-0201 will follow the 505(b)(2) regulatory pathway in the U.S.

i Symphony Health Solutions Report, 2014.